Likelihood of Approval and Phase Transition Success Rate Model – ETX-155
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models.
Likelihood of Approval (LoA) – Industry
ETX-155 Drug Details
ETX-155 is under development for the treatment of major depressive disorder (MDD), perimenopausal depression and focal onset seizures (FOS). The drug candidate is administered through oral route. It is a next-generation, neuroactive steroid new chemical entity (NCE) that acts by targeting GABA A type receptor.
The data is segmented by drug name and intervention type and shows the current likelihood of approval for the drug compared to both the indication benchmark and the industry benchmark so you can:
- Get information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
- Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR
- Use PTSR and LOA information and event-driven changes for your investment decisions to generate alpha
Additionally, this data is updated regularly based on events that take place which impact the clinical development process. GlobalData uses its proprietary machine learning models to track event-driven changes in LOA and PTSR and provides the quantitative changes to the likelihood of success along with the qualitative reasoning why the likelihood of approval has changed.
|Quick View – LOA Data|
|Report Segments||· Drug type
· Intervention type
|Drug Development Status||·|
Reasons to Buy
- Allows clients to track and predict specific likelihood of approval and phase transition success rates of a drug using a combination of machine learning and proprietary models
- Obtain information on LOA and PTSR for competitors’ drugs to plan your clinical development, commercialization and marketing strategies
- Track event-driven changes in LOA and PTSR benchmarked against indication and industry values
- Use PTSR and LOA information and event driven changes for your investment decisions to generate alpha
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Frequently Asked Questions
The probability of a drug ultimately receiving market authorization
The probability of a drug’s advancement to the next stage of clinical development
GlobalData’s Drug-Specific Likelihood of Approval (LoA) calculates the Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) customized to individual drug. The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases.
- Drugs which have been approved in the past 10 years
- Drugs which have failed during clinical development in the past 18 years
- Drugs which are currently in development
Drug Phase Scope:
- Phase I, Phase II, Phase III, and Pre-Registration development stage
Drug Geography Scope:
- Drugs must meet one of the following criteria to be included in the model:
- The developer has specified the US as an intended market for approval.
- The developer has not specified any country as an intended market for approval, i.e. the “Drug Geography” is listed as “Global”
Drug Type Scope:
- Innovator drugs and biosimilars
Entity Type Scope:
Only drugs in development by companies are included in the model.
- Diagnostics, Imaging Agents, Biomarkers, stents and other drug delivery devices (covered in GlobalData’s Medical Intelligence Center).
- Nutraceuticals, dietary supplements, alternative medicines, imaging agents, radio emitter, transplants, transfusions, fillers, cosmetics, probiotics, antiseptics, antacids, mobilizing agents, veterinary drugs and drugs not seeking approval.
- Generic drugs
- Innovative drugs in Preclinical or Discovery Stage.
- Pipeline drugs sponsored by a Government or Institution.
- Drugs with a specific Drug Geography not the United States.
Methodology – Machine Learning
- GlobalData’s Drug-Specific Likelihood of Approval (LoA) models utilizes many attributes from Drugs, Clinical Trials, Review Designations and Company. The proprietary, machine learning algorithm is developed based on the impact of a specific attribute on PTSR and LoA.
|Drug attributes||Trial attributes||Company attributes||Regulatory attributes|
- The attributes with substantial impact on PTSR and LoA have the maximum weightage in the model, while the less impactful attributes have intermediate or low weightage.
- PTSR and LoA scores are dynamic and are modified automatically with dynamic updates in drug, trials and company records. Time dependent variation is largely witnessed in the Clinical Trial attributes and influences the scores in positive or negative direction depending on its implication. This offers the user to examine the real time trajectory of clinical phase transition probability for a drug.
Methodology – Proprietary Model
- GlobalData’s ML algorithm utilizes historical data to determine the probability of successful progression and market authorization for pipeline drugs from their current development stage. The historical data set is prepared to train the ML classifier. Once the algorithm is trained and recognizes a specific pattern, it is applied to the test data. The key learning are further tuned for hyperparameters to derive the optimum model.
ML Model Development
- The ML model is further supplemented with an additional algorithm proprietary to GlobalData to predict PTSR and LoA. Each of the data attributes are assigned a weighted average score based on its direct impact on a drug’s clinical transition. The weighted average score represents a scale between a minimum to a maximum value based on the Raw Scores. The final score of an attribute is achieved by multiplying the Raw Score with the Weighted Score for each data attribute. All scores are added to determine the PTSR value.
- LoA is calculated by compounding the PTSR at each stage the drug is yet to progress through. For example, to calculate the LoA for a drug in Phase I, the following formula is used: PTSR % Phase Ix PTSR % Phase II x PTSR % Phase III x PTSR % Pre-Registration.
Get in touch to find out about our multi-purchase discounts
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.